MD Roundtable Part 3: Impact of Keratoconus on Patient and Refractive Surgery Practice

Eric D. Donnenfeld, MD

Ophthalmic Consultants of Long Island and Connecticut
Trustee, Dartmouth Medical School
Clinical Professor of Ophthalmology
New York University
New York, NY

Ashley Brissette, MD

Assistant Professor of Ophthalmology
Cornea, Cataract, and
Refractive Specialist
Weill Cornell Medicine
New York-Presbyterian Hospital
New York, NY

Terry Kim, MD

Professor of Ophthalmology
Duke University School of Medicine
Chief, Cornea and External Disease Division
Director, Refractive Surgery Service
Duke University Eye Center
Durham, NC

Richard Lindstrom, MD

Program Director
Founder and Attending Surgeon
Minnesota Eye Consultants
Minneapolis, MN

Neda Shamie, MD

Partner
Cornea, Cataract, and Refractive Surgeon
Maloney-Shamie Vision Institute
Los Angeles, California
Clinical Associate Professor
University of Southern California
Keck School of Medicine
Los Angeles, CA

William B. Trattler, MD

Cornea, Cataract, and
Refractive Surgeon
Center for Excellence in Eye Care
Miami, Florida
Clinical Associate Professor
Herbert Wertheim College of
Medicine at Florida
International University
Miami, FL

Elizabeth Yeu, MD

Moderator
Virginia Eye Consultants
Medical Director, CVP Mid-Atlantic
Cornea, Cataract, External Disease and Refractive Surgery
Assistant Professor, Department of Ophthalmology
Eastern Virginia Medical School
Norfolk, Virginia

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Eric D. Donnenfeld, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allegro, Allergan, Avellino, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Covalent, BVI, Blephex, Dompé, ELT Sight, EyePoint Pharmaceuticals, Foresight, Glaukos, Ivantis, Johnson & Johnson Vision, Kala Pharmaceuticals, Katena, Lacripen, LensGen, Mati Therapeutics, MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novartis, Novaliq, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Oyster Point Pharma, Pfizer, Pogotec, Ocuhub, Omeros, PRN, RegenerEyes, ReTear, RPS, Shire, Strathspey Crown, Sun Pharmaceutical Industries, Surface, Tarsus, Tearlab, Tearscience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Venture, and Visus. Stock/Shareholder: Avedro, CorneaGen, Covalent, ELT Sight, EyePoint Pharmaceuticals, Glaukos, Ivantis, Lacripen, LensGen, Mati Therapeutics, MDBackline, Mimetogen, Novabay, Ocuhub, Ocular Innovations, Oculis, Orasis Pharmaceutical, Pogotec, RegenerEyes, ReTear, RPS, Strathspey Crown, Surface, Tarsus, TearLab, Veracity, Versant Ventures, Visionary Ventures, and Visus.

Ashley Brissette, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Bruder, Carl Zeiss Meditec, Eyevance, Kala Pharmaceuticals, and Ocular Therapeutix. Grant/Research Support: Alcon Vision.

Terry Kim, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon Vision, Allergan, Avedro, Avellino Labs, Azura Ophthalmics, Bausch + Lomb, CorneaGen, Dompé, Eyenovia, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Ocular Therapeutix, Oculis, Omeros, Presbyopia Therapies, Sight Sciences, Simple Contacts, Surface, and Carl Zeiss Meditec. Stock/Shareholder: Avellino Labs, CorneaGen, Eyenovia, Kala Pharmaceuticals, Ocular Therapeutix, Omeros, Presbyopia Therapies, and Simple Contacts.

Richard Lindstrom, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Acufocus, Aerie Pharmaceuticals, Alcon Vision, Allegro, Bausch Health, Johnson & Johnson Vision, Kala Pharmaceuticals, Imprimis, Surface Ophthamics, Novartis, and Ocular Therapeutix.

Neda Shamie, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Avellino, Glaukos, Staar Surgical, and Tarsus.

William B. Trattler, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Bausch + Lomb, Carl Zeiss Meditec, CXLO, Johnson & Johnson Vision, and Oculus. Speaker’s Bureau: Alcon Vision, Carl Zeiss Meditec, Johnson & Johnson Vision, and Oculus. Stock/Shareholder: Avedro, CXLO, and Trefoil.

Elizabeth Yeu, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Avedro, Bausch + Lomb, BioTissue, Beaver Visitec, BlephEx, Bruder, Carl Zeiss Meditec, CorneaGen, Dompé, Expert Opinion, EyePoint Pharmaceuticals, Guidepoint, Johnson & Johnson Vision, Kala Pharmaceuticals, Lensar, Merck, Mynosys, Novartis, Ocular Science, Ocular Therapeutix, Ocusoft, Omeros, Oyster Point Pharma, Science Based Health, Shire, Sight Sciences, Sun Pharmaceutical Industries, Surface, Thea, Tarsus, TopCon, TearLab, and Visus Therapeutics. Grant/Research Support: Alcon Vision, BioTissue, Ocular Science, TopCon, and TearLab. Stock/Shareholder: BlephEx, CorneaGen, Melt, Ocular Science, Oyster Point Pharma, and Tarsus.

The Evolve and The Fundingsland Group planners have no financial relationships with commercial interests.